Researchers reported an anchored biomarker model that maps amyloid-positive disease progression and transition dynamics using biologically grounded latent dimensions. The approach suggests that biomarker-only factors independently predict clinical progression while revealing how transition timings shift with disease duration. The study’s focus on probabilistic modeling is intended to improve the interpretability of progression estimates drawn from biomarker kinetics, which can vary across individuals and stages. For drug developers and trial designers, the actionable element is a potentially better way to connect biomarker readouts to expected clinical change over time—especially for anti-amyloid strategies where endpoints often hinge on timing and stage assumptions.